4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

This international multidisciplinary document intends to provide clinicians with evidence-
based practical patient-centered recommendations for evaluating patients and decedents …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

Background: Mutations in desmoplakin (DSP), the primary force transducer between cardiac
desmosomes and intermediate filaments, cause an arrhythmogenic form of cardiomyopathy …

Myocardial diseases are associated with an increased risk of potentially fatal cardiac
arrhythmias and sudden cardiac death/cardiac arrest during exercise, including hypertrophic …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Epidemiological and biological plausibility studies support a cause-and-effect relationship
between increased levels of physical activity or cardiorespiratory fitness and reduced …

Sudden cardiac death (SCD) is the leading cause of mortality in athletes during sport. A
variety of mostly hereditary, structural, or electrical cardiac disorders are associated with …